ArticleCureus2025
Cognitive Resilience for the Prevention of Mild Cognitive Impairment in Subjective Cognitive Decline: A Monte Carlo Simulation of a Digital Therapeutic Targeting Dementia Risk Factors.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Subjective cognitive decline (SCD) is an early marker of neurodegenerative disease and a target for preventative interventions. With advances in smartphone-based clinical interventions and understanding of modifiable risk factors for cognitive decline, this simulation study aimed to estimate the potential benefits of a prescription digital therapeutic (PDT) with multi-risk-factor modification on the cognitive trajectory of individuals with SCD. We constructed a Monte Carlo simulation to model progression to mild cognitive impairment (MCI) over a five-year period. Methods A virtual cohort of 10,000 patients with SCD was simulated over five years. Baseline annual risk of progression to MCI was set at 10%. A PDT was assumed to yield a 30% relative risk reduction, modulated by adherence levels (70% full, 20% partial, 10% none). Additionally, 14 modifiable dementia risk factors were modeled based on the 2024 Lancet Commission update, with each risk factor assigned a prevalence, modifiability flag, relative risk reduction, and effectiveness rate. Risk adjustments were applied multiplicatively, and outcomes were tracked annually. Results After five years, 6,487 (65%) of patients remained cognitively stable, 2,496 (25%) progressed to MCI, and 1,017 (10%) dropped out. These results represent a significant improvement over the expected 41% progression rate in untreated SCD populations. Reductions in physical inactivity, hypertension, hearing loss, and social isolation contributed substantially to outcome improvements, particularly when multiple risk factors were addressed concurrently. Conclusion The incorporation of a PDT with systematic modification of multiple modifiable dementia risk factors demonstrates a meaningful reduction in cognitive decline risk among individuals with SCD. These findings highlight the potential of integrated digital-first strategies to meaningfully delay cognitive decline and may inform future PDT trials and dementia prevention programs. Validation in prospective clinical trials is warranted to confirm these simulation-based findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.